The plan extends Trump’s tariffs to generics, which fill about 90% of U.S. prescriptions, in an effort to shift production home. But without a formal implementing order, its scope—and its potential to raise prices or worsen shortages—remains unclear.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
If you are a current subscriber, and had an account on our previous site, you already have an account. If you have not yet logged into our new site, click here to reset your password.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
